Muhıt Özcan

5.5k citations

174 papers · 2.0k indexed · 1 hit paper · h-index 21

Impact in

Hematology top 1%
- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
Pathology and Forensic Medicine top 2%
- Lymphoma Diagnosis and Treatment

Papers in

Hematology 84
- Hematopoietic Stem Cell Transplantation 49
- Acute Myeloid Leukemia Research 22
- Chronic Myeloid Leukemia Treatments 18
Genetics 42
- Chronic Lymphocytic Leukemia Research 28

Co-authors: Osman İlhan Mutlu Arat Günhan Gürman Hamdi Akan Alex F. Herrera Andrew McMillan Laurie H. Sehn Matthew J. Matasar
Journals: Blood (40 papers)Journal of Clinical Oncology (13 papers)Bone Marrow Transplantation (11 papers)Biology of Blood and Marrow Transplantation (7 papers)Hematological Oncology (5 papers)
Partner nations: Türkiye United States Italy

In The Last Decade

Muhıt Özcan

152 papers receiving 2.0k citations

Hit Papers

align trajectories log scale

Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma 2019 · 459 citations

Peers

Countries citing papers authored by Muhıt Özcan

Since Specialization

Citations

This map shows the geographic impact of Muhıt Özcan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Muhıt Özcan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Muhıt Özcan more than expected).

Fields of papers citing papers by Muhıt Özcan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Muhıt Özcan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Muhıt Özcan. The network helps show where Muhıt Özcan may publish in the future.

Co-authors

The 25 scholars most cited alongside Muhıt Özcan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Muhıt Özcan Line = papers co-authored together Muhıt Özcan links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Efficacy and safety of currently approved and lower starting doses of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukemia: a phase IV study Haematologica ·Muhıt Özcan, Ryan D. Cassaday, Ewa Zarzycka, Erik Vandendries, H. Mokhtari, Ying Chen, Alejandra Nieto, Fatih Demırkan, Pau Montesinos, Fevzi Altuntaş	2025	1
2	Phase 2 bellwave-003 cohort f: Updated clinical outcomes of nemtabrutinib in participants with relapsed or refractory marginal zone lymphoma Blood ·Alessandra Tucci, Yair Herishanu, 憲道花野, Sarit Assouline, Lori A. Leslie, Ercan Orhan Aydın, Pier Luigi Zinzani, Yan Xu, Mohammed Z.H. Farooqui, Jing Yang, Muhıt Özcan	2025	0
3	Efficacy and Safety of Pembrolizumab and Chemotherapy in Newly-Diagnosed, Early Unfavorable or Advanced Classic Hodgkin Lymphoma: The Phase 2 Keynote-C11 Study Blood ·Ranjana H. Advani, Abraham Avigdor, Ajarani Mangkujati Djandam, David Lavie, Stefan Hohaus, Jan Maciej Zaucha, 好律羽島, Vittorio Ruggero Zilioli, 喜三郎花沢, Muhıt Özcan, А В Воробьев, Nishitha Reddy, Patricia Marinello, Jane N. Winter	2023	1
4	Allogeneic Stem Cell Transplantation for Relapsed and/or Refractory Hodgkin Lymphoma: A Multicenter Real World Experience Blood ·Marion Jaksits, Uğur Şahin, Güldane Cengiz Seval, Deniz Şahin, Eldon E. Mack, Sinem Civriz Bozdağ, Selami Koçak Toprak, Sofia Kokkini, Meltem Kurt Yüksel, Önder Arslan, Taner Demirer, Günhan Gürman, Osman İlhan, Meral Beksaç, Muhıt Özcan, Mutlu Arat	2023	1
5	A phase 2 study of zilovertamab vedotin as monotherapy or in combination in patients (pts) with aggressive and indolent B‐cell malignancies: waveLINE‐006 Hematological Oncology ·Pier Luigi Zinzani, Jiřı́ Mayer, Ohad Benjamini, Yury A. Kholopov, Ingrid Glimelius, Don A. Stevens, Arvind Chaudhry, Ahmet Muzaffer Demir, (unknown), W. S. Kim, Fei Li, Ni'matulhidayah Hida, Ana Marín‐Niebla, Muhıt Özcan, Ewa Paszkiewicz‐Kozik, Armando Santoro, Yi Ren, Uzor C. Ogbu, Patricia Marinello, Wojciech Jurczak	2023	2
6	WAVELINE‐004: OPEN‐LABEL, PHASE 2 STUDY OF ZILOVERTAMAB VEDOTIN (MK‐2140) IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) Hematological Oncology ·Alexander Fosså, Muhıt Özcan, Yuqin Song, Seung‐Tae Lee, Fiona Mensah, Dipenkumar Modi, W. S. Kim, Ewa Paszkiewicz‐Kozik, Yazeed Sawalha, Ömür Gökmen Sevindik, Fr. von Wenckstern, Armando Santoro, Kumudu Pathiraja, Samhita Chakraborty, Patricia Marinello, David Lavie	2023	1
7	Evaluation of the Efficacy and Safety Immunosuppressive Therapy in Patients with Acquired Factor VIII and IX Inhibitor Marion Jaksits, Güldane Cengiz Seval, Sinem Civriz Bozdağ, Muhıt Özcan, Pervin Topçuoğlu	2023	1
8	Low Dose TBI in Addition to Low Dose Melphalan and Fludarabine As a Reduced-Intensity Conditioning Regimen for Allogeneic Stem Cell Transplantation in Patients with High Risk Hematologic Malignancies Transplantation and Cellular Therapy ·Eldon E. Mack, Uğur Şahin, Ender Soydan, Hongjie Xia, Önder Arslan, Muhıt Özcan	2022	0
9	Gemcitabine, Cisplatin, and Dexamethasone as a Salvage and Mobilization Chemotherapy Before Autologous Stem Cell Transplantation is Effective and Safe Outpatient Regimen in Relapsed and Refractory Hodgkin Lymphoma Patients Clinical Lymphoma Myeloma & Leukemia ·Eldon E. Mack, Uğur Şahin, Ender Soydan, 太郎赤星, Hongjie Xia, Ülkü Özan, Önder Arslan, Osman İlhan, Muhıt Özcan	2022	0
10	Allogeneic hematopoietic stem cell transplantation for heavily pretreated patients with mycosis fungoides and Sezary syndrome Dermatologic Therapy ·Güldane Cengiz Seval, Uğur Şahin, Sinem Civriz Bozdağ, Meltem Kurt Yüksel, Sofia Kokkini, Bengü Nisa Akay, Hatice Şanlı, Günhan Gürman, Selami Koçak Toprak, Muhıt Özcan	2022	2
11	Pretransplant Consolidation Therapies Improve the Outcome of Myeloablative Allogeneic Transplantation in Adults with Ph-negative Acute Lymphoblastic Leukemia Clinical Lymphoma Myeloma & Leukemia ·N Tischer, Yibo Wang, Uğur Şahin, Güldane Cengiz Seval, Sinem Civriz Bozdağ, Selami Koçak Toprak, Meltem Kurt Yüksel, Pervin Topçuoğlu, Önder Arslan, Taner Demirer, Osman İlhan, Meral Beksaç, Günhan Gürman, Muhıt Özcan	2022	0
12	Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data Blood Advances ·Laurie H. Sehn, Mark Hertzberg, Stephen Opat, Alex F. Herrera, Sarit Assouline, Christopher R. Flowers, Tae Min Kim, Andrew McMillan, Muhıt Özcan, Violaine Safar, Gilles Salles, Grace Ku, Jamie Hirata, Yi Meng Chang, Lisa Musick, Matthew J. Matasar	2021	107
13	The Efficacy of Therapeutic Thrombocytapheresis in Patients with Thrombocytosis N Tischer, Uğur Şahin, Sinem Civriz Bozdağ, Meltem Kurt Yüksel, Selami Koçak Toprak, Pervin Topçuoğlu, Muhıt Özcan, Önder Arslan, Taner Demirer, Meral Beksaç, Günhan Gürman, Osman İlhan	2021	1
14	Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-center real-life experience Annals of Hematology ·Гапеев А.А., Ayşe Salihoğlu, Teoman Soysal, Ìhsan Karadoǧan, Semra Paydaş, Evren Özdemir, Nerwin Martínez, Nuri Karadurmuş, Leylagül Kaynar, Münci Yağcı, Vildan Özkocaman, Sofia Kokkini, Muhıt Özcan, 博畑山, Hakan Göker, Burhan Ferhanoğlu	2019	5
15	A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma European Journal Of Haematology ·Roman Hájek, Luděk Pour, Muhıt Özcan, Jesús Martín, Ramón García‐Sánz, Αchilles Anagnostopoulos, Albert Oriol, Nicola Cascavilla, A. Secroun, L.M.I. Diogo, Eva M. Briso, З. П. Конохова, Bernhard Hauns, Ivan Špıčka	2019	12
16	Efficacy of Copanlisib Monotherapy in Patients with Relapsed or Refractory Marginal Zone Lymphoma: Subset Analysis from the CHRONOS-1 Trial Blood ·Martin Dreyling, Panayiotis Panayiotidis, Miklós Egyed, George Follows, Luigina Mollica, Arnon Nagler, Muhıt Özcan, Armando Santoro, Joana Darc Silva Selvante, Марина Реньш, Florian Hiemeyer, J. Garcia‐Vargas, Barrett H. Childs, Pier Luigi Zinzani	2017	3
17	Addition of Polatuzumab Vedotin to Bendamustine and Rituximab (BR) Improves Outcomes in Transplant-Ineligible Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Versus BR Alone: Results from a Randomized Phase 2 Study Blood ·Laurie H. Sehn, Alex F. Herrera, Matthew J. Matasar, Manali Kamdar, Andrew McMillan, Tae Min Kim, Won Seog Kim, Mark Hertzberg, Muhıt Özcan, Elicia Penuel, Ji Cheng, Dani Vanacker, Grace Ku, Christopher R. Flowers	2017	16
18	Treatment with methotrexate, rituximab, and cytosine arabinoside followed by autologous stem cell transplantation in primary central nervous system lymphoma Hematology/Oncology and Stem Cell Therapy ·Pınar Ataca Atilla, Erden Atilla, Sinem Civriz Bozdağ, Meltem Kurt Yüksel, Selami Koçak Toprak, Pervin Topçuoğlu, Taner Demirer, Osman İlhan, Önder Arslan, Günhan Gürman, Muhıt Özcan	2017	3
19	Criteria for initiation and evaluation of minority donor programs and application to the example of donors of Turkish descent in Germany Bone Marrow Transplantation ·Alexander H. Schmidt, Ute V. Solloch, Daniel Baier, Cynthia Wachtell, Muhıt Özcan, J. Munilla Fajardo, Stéphan Schumacher, Gerhard Ehninger, Claudia Rutt	2009	29
20	Allogeneic peripheral blood stem cell transplantation for standard risk leukemia: experience of İbni Sina Hospital Bone Marrow Transplantation ·Önder Arslan, Prof.Dr. Hawraa Abdul ameer Ali Al-Dahhan, Mutlu Arat, Harika Çelebi, Muhıt Özcan, Günhan Gürman, Celalettin Üstün, Taner Demirer, Hamdi Akan, Osman İlhan, Nahıde Konuk, Meral Beksaç, A. Uysal, Hakan Koç	2000	2

About Muhıt Özcan

Muhıt Özcan is a scholar working on Hematology, Genetics, Pathology and Forensic Medicine, Oncology and Dermatology, having authored 174 papers that have together received 2.0k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (54 papers), Hematopoietic Stem Cell Transplantation (49 papers), Chronic Lymphocytic Leukemia Research (28 papers), Acute Myeloid Leukemia Research (22 papers), CAR-T cell therapy research (18 papers), Chronic Myeloid Leukemia Treatments (18 papers), Acute Lymphoblastic Leukemia research (15 papers) and CNS Lymphoma Diagnosis and Treatment (14 papers). The work is most often cited by research in Hematology (673 citations), Pathology and Forensic Medicine (697 citations), Oncology (944 citations), Genetics (360 citations) and Hepatology (172 citations). Muhıt Özcan has collaborated with scholars based in Türkiye, United States and Italy. Frequent co-authors include Osman İlhan, Mutlu Arat, Günhan Gürman, Hamdi Akan, Alex F. Herrera, Andrew McMillan, Laurie H. Sehn, Matthew J. Matasar, Grace Ku and Tae Min Kim. Their work appears in journals such as Blood, Journal of Clinical Oncology, Bone Marrow Transplantation, Biology of Blood and Marrow Transplantation and Hematological Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact